BRAF V600E

BRAF V600E is a specific change in the BRAF gene where the amino acid valine is swapped for glutamic acid at position 600 of the BRAF protein. This single change keeps the BRAF protein "stuck on," driving cells to grow and divide continuously. It is one of the most common cancer-driving mutations and, when present, often opens the door to specific targeted drug therapies.

Origin

The BRAF gene was identified in the 1980s as a human counterpart to a viral cancer-causing gene (v-raf). In 2002, a landmark study led by Davies and colleagues at the Wellcome Sanger Institute discovered that BRAF mutations, overwhelmingly V600E, were present in a large share of melanomas, launching an entire field of BRAF-targeted drug development.

Significance in Asbestos Context

For patients with asbestos-related cancers, BRAF V600E is uncommon but worth knowing about because it can change treatment options. In pleural mesothelioma, BRAF V600E is rare, but in some lung cancers it is found in a small percentage of cases and qualifies patients for FDA-approved combination therapy (a BRAF inhibitor such as dabrafenib plus a MEK inhibitor such as trametinib). If your tumor was tested and found to be BRAF V600E positive, this does not change the fact that asbestos exposure caused or contributed to your disease. The mutation describes how the cancer behaves, not what caused it. Defense experts sometimes argue that genetic mutations point to non-asbestos causes; in reality, mutations like BRAF V600E commonly arise in cells that have been damaged by carcinogenic exposures.

Example Sentence

After her lung adenocarcinoma was diagnosed, molecular testing showed a BRAF V600E mutation, which made her eligible for a targeted oral therapy in addition to her asbestos-related claim.

Related Terms

Targeted Therapy, Molecular Profiling, EGFR Mutation, Mesothelioma, Lung Cancer, MAPK Pathway

Notes

• Ask your oncologist whether your tumor has had comprehensive molecular or next-generation sequencing (NGS) testing. BRAF V600E is part of most standard panels for lung cancer and is sometimes tested in mesothelioma.
• If you are BRAF V600E positive, ask specifically about FDA-approved BRAF/MEK inhibitor combinations and any open clinical trials; a second opinion at an NCI-designated cancer center can be valuable.
• Keep copies of all pathology and molecular testing reports. These documents matter both for treatment decisions and for documenting the specifics of your disease in a legal claim.
• A positive BRAF V600E result does not rule out asbestos as a cause of your cancer; discuss with your legal team how to respond if defense experts try to use molecular findings to dispute causation.